Psoriasis News and Research

Latest Psoriasis News and Research

Recommendations in pediatric palliative care

The future of pediatric and perinatal palliative care should include accepting parents’ need for proximity to the child, combining the strategies of palliative and intensive care physicians, improving healthcare providers’ listening skills, and involving multiple disciplines, recommend researchers.

11 Oct 2012

Simple test confirms correct catheter placement

Injecting sodium bicarbonate into a peripheral intravenous catheter is a straightforward means of testing its placement and patency in mechanically ventilated children, say researchers.

10 Oct 2012

Hemophilia bleeding risk ‘low’ for childhood sports

Vigorous physical activity is associated with a moderate but transient bleeding risk for hemophilia, resulting in an overall low risk for bleeds, suggests a study of Australian children.

10 Oct 2012

Transfused blood age does not impact outcomes in premature babies

Using fresh red blood cells for premature babies who need blood transfusions does not improve outcomes over use of standard blood bank donations, show study findings published in JAMA.

9 Oct 2012

Isolated fetal echogenic bowel ‘may be benign’

Results of a Dutch study show that the majority of fetuses with fetal echogenic bowel carry a good prognosis.

9 Oct 2012

Myocutaneous flap shows promise in pediatric Achilles tendon repair

A free partial latissimus dorsi myocutaneous flap can be used for the treatment of severe contracture of the Achilles tendon and posterior ankle in children, and achieves satisfactory form and function, the results of a case series indicate.

8 Oct 2012

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

XenoPort, Inc. announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF).

5 Oct 2012

FDA grants Fast Track designation to XBiotech’s Xilonix for treatment of cachexia

XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation for its anti-cachexia drug Xilonix.

4 Oct 2012

Structured deliberation improves neonatal decision-making process

The implementation of a structured multiprofessional medical ethical decision-making process could improve decision-making in neonatal intensive care units, show study results from the Netherlands.

3 Oct 2012

Steroid use during tonsillectomy does not raise excessive bleeding risk

Children who are given dexamethasone during tonsillectomy are not more likely to experience excessive bleeding after surgery than those who do not receive the steroid perioperatively, study findings suggest.

2 Oct 2012

Multiple Epo doses with hypothermia offers neonate neuroprotection

Multiple doses of erythropoietin in combination with hypothermia could be neuroprotective in neonates with hypoxic‑ischemic encephalopathy, say researchers.

1 Oct 2012

CBT ‘has no impact’ on juvenile fibromyalgia physical activity

Cognitive behavior therapy is not associated with increased physical activity levels in adolescents with juvenile fibromyalgia, research shows.

1 Oct 2012

FDA approves Stiefel’s Sorilux Foam sNDA to treat for scalp psoriasis

Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

Abbott receives FDA approval for Humira to treat ulcerative colitis

The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.

29 Sep 2012

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."

28 Sep 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Biogen Idec and Swedish Orphan Biovitrum (Sobi) today announced positive results from B-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.

27 Sep 2012